Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Cornelia de Lange syndrome (CdLS), also called Brachmann-de Lange syndrome or De Lange syndrome, is described in the packet definition as a rare syndrome characterized by low birth weight, delayed growth, intellectual disability, behavioral problems, and a distinctive facial appearance. The onset category in this packet is congenital. According to GeneReviews, published prevalence estimates range from 1 in 100,000 to as high as 1 in 10,000, and an estimate from the EUROCAT dataset puts the classic form at about 1 in 50,000; GeneReviews notes that prevalence is difficult to estimate because individuals with milder or variable features are likely under-recognized. The packet lists six numbered subtypes (Cornelia de Lange syndrome 1 through 6). The packet does not certify specific gene associations or an inheritance pattern for this entry.
GeneReviews describes CdLS as a clinical spectrum ranging from mild to severe, and states that individuals with a milder phenotype may represent the majority of those with the condition. Prenatal-onset growth failure is described as present in a majority of affected individuals, with proportionate short stature becoming more pronounced by about six months of age. Frequencies in a GeneReviews table of features include feeding difficulties (95%), growth failure (95%), intellectual disability (95%, typically severe to profound in those with classic CdLS), small hands and feet (90%), microbrachycephaly (90%), long eyelashes (90%), and dental problems (90%). Hypertrichosis is reported in 80%, hearing loss in 80% (with 40% having profound sensorineural hearing loss, although hearing loss may improve over time), and micrognathia in 80% of those with classic features. Gastroesophageal reflux disease is listed at 75%, nasolacrimal duct obstruction at 70%, ptosis at 60%, self-injurious behavior at 56%, and sleep difficulties at 50%. Less frequent features include scoliosis (33%), high arched palate with clefting (30%), congenital heart defects (30%, most commonly pulmonic or peripheral pulmonic stenosis, ventricular septal defect, or atrial septal defect), seizures (25%), and oligodactyly (25%). Synophrys is reported in 98% of individuals with classic features. GeneReviews gives the overall range of IQ as broad, from below 30 to 102, with an average of 53, and states that expressive language is often more compromised than receptive language.
The packet does not list any genes, OMIM identifiers, or inheritance patterns for this entry, so specific genetic causes and inheritance are not certified here. The packet definition attributes most cases to mutations in genes, but those genes are not certified in the packet's gene field. GeneReviews describes the molecular genetic basis of CdLS as having led to recognition of individuals with milder or atypical features. GeneReviews also reports genotype-phenotype correlations, stating that individuals with missense variants and in-frame deletions in one gene discussed in that chapter have been found to have less severe growth deficiency, milder intellectual disability, and fewer structural anomalies than those with loss-of-function variants. It further notes that growth may be less severely affected in those with milder overall features or mosaic pathogenic variants. The packet lists six subtypes of the condition but does not specify a gene for each.
According to GeneReviews, CdLS constitutes a clinical spectrum, and an international consensus statement has defined cardinal and suggestive features along with a scoring system to distinguish classic and non-classic CdLS. Suggestive clinical findings listed by GeneReviews include a distinctive craniofacial appearance (including microcephaly, synophrys, long thick eyelashes, a short nasal bridge, a thin upper lip, a highly arched palate, small widely spaced teeth, and micrognathia), growth failure that may be detected prenatally, developmental delay or intellectual disability ranging from mild to profound, limb abnormalities, and hypertrichosis. On radiographs, a short first metacarpal resulting in a proximally placed thumb is described as useful in diagnosis when limb deficiencies are absent. GeneReviews states that the diagnosis is established in a proband with these clinical features and/or by molecular genetic testing identifying a pathogenic or likely pathogenic variant in one of several genes named in that chapter. Testing approaches described include multigene panels, serial single-gene testing, and comprehensive genomic testing such as exome or genome sequencing. GeneReviews notes that variants of uncertain significance cannot be used to confirm or rule out the diagnosis. Its differential diagnosis section states that phenotypic overlap with CdLS may be observed in other monogenic disorders, chromosome abnormalities, and fetal alcohol syndrome.
The packet certifies no foundational therapies or FDA-approved treatments for this entry. GeneReviews describes management that is organized by manifestation. For poor weight gain, it lists feeding therapy, with gastrostomy tube placement possibly required for persistent feeding issues. For gastroesophageal reflux disease, it lists proactive management with a low threshold for medical therapy and lists fundoplication as an option for severe symptoms. Malrotation is listed as treated with surgical correction. For epilepsy, GeneReviews lists standard anti-seizure medication treatment under an experienced neurologist and states that none has been demonstrated effective specifically for CdLS. For developmental delay and intellectual disability, it lists early speech therapy and early intervention services, and for limb defects it states that surgical intervention of the arms and hands is rarely needed. Hearing aids are described as potentially helpful for hearing loss, while cleft palate, dental anomalies, congenital heart defects, and eye findings are each listed as managed through standard care by the relevant specialty. GeneReviews also describes a surveillance schedule that includes ophthalmologic evaluation at least annually and audiology evaluation at least annually in childhood and adolescence, and mentions published clinical management guidelines for CdLS.
The packet does not include a natural history field, and long-term outcomes are not certified here. The GeneReviews clinical description reports some developmental milestone figures: half of children are described as walking by 24 months and 95% by age ten, and half as able to feed themselves by age three years and 95% by age ten. It also describes mean height and weight as below the fifth centile throughout life in individuals with classic CdLS, and states that hearing loss may improve over time. These figures describe reported groups and do not describe the course in any individual.
The packet lists six ClinicalTrials.gov records associated with Cornelia de Lange syndrome. NCT01793168, a rare disease patient registry and natural history study coordinated by Sanford Health, is listed as recruiting beginning in July 2010. NCT04381897, sponsored by Johns Hopkins University, is a Phase 2 study titled as examining N-acetylcysteine for repetitive and self-injurious behaviors in CdLS; it is listed as not yet recruiting, beginning in November 2026. NCT06740162, the Physical Activity and Community EmPOWERment Project from the University of North Carolina, Chapel Hill, is listed as recruiting, beginning in January 2025. NCT05829668, a behavioral assessment and treatment study of problem behavior in children with CdLS from the Kennedy Krieger Institute, is listed as recruiting, beginning in August 2023. NCT06789783, a Phase 2 study from the University of Milan titled as assessing the effects of lithium treatment in CdLS, is listed as recruiting, beginning in May 2024. NCT04463316, a study titled GROWing Up With Rare GENEtic Syndromes led by Dr. Laura C. G. de Graaff-Herder, is listed as recruiting, beginning in October 2018. Trial titles do not establish that any intervention is effective.
Data assembled from 5 of 12 sources · Last updated Nov 17, 2026, 1:21 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Cornelia de Lange syndrome
6 trials found
AI-curated news mentioning Cornelia de Lange syndrome
Updated May 13, 2026
A recent study highlights unusual head and neck vascular patterns in two patients with Cornelia de Lange syndrome, providing insights into associated cerebrovascular anomalies. This case-based analysis may inform future research and clinical approaches to this rare condition.
A case report identifies a de novo start-loss variant in the NIPBL gene linked to mild type 1 Cornelia de Lange syndrome in an Iranian family. This finding contributes to the understanding of genetic factors in this rare condition.